🔴 Clearpoint Neuro is trading 15.84% down now at $12.88 after AMT-130 missed statistical significance

Clearpoint Neuro is trading 15.84% down at $12.88 after a September 29 report linked the selloff to disappointing uniQure AMT-130 results.

• The Huntington’s disease treatment did not reach statistical significance on a primary measure at 48 months.
• Clearpoint supplies the MRI-guided navigation platform and SmartFlow cannula used for delivery, raising concerns about future procedure-related revenue. The report cited Clearpoint down 24% and uniQure down 55%, figures that differ from the supplied live price context; it gave no Clearpoint volume data.